, Concernant les caractéristiques cliniques de l'IC, environ 60% des patients avaient une cardiomyopathie ischémique avec des taux moyens de BNP et de NT-proBNP respectivement

C. Gillot, J. Paupe, and H. Schmitt, Universalis: Appareil circulatoire humain

. Universalis, , p.24, 2016.

G. J. Tortora and S. R. Grabowski, Principes d'anatomie et de physiologie. Bruxelles, 1994.

E. Alché and . -p-d', Comprendre la physiologie cardiovasculaire. Paris: Médecine-Sciences Flammarion, 2008.

L. Sherwood and . Physiologie, , 2006.

C. Latrémouille and F. Lintz, Anatomie du coeur. EMC-Cardiol-Angeiol, vol.2, issue.3, pp.231-251, 2005.

F. , organes, systèmes et appareils-Niveau PCEM2-DCEM1, 2016.

M. Fenton and M. Burch, Understanding chronic heart failure, Arch Dis Child. 1 sept, vol.92, issue.9, pp.812-818, 2007.

R. Ferrari, C. Balla, and A. Fucili, Heart failure: an historical perspective, Eur Heart J Suppl. nov, vol.18, pp.3-10, 2016.

R. Bianucci, R. D. Loynes, M. L. Sutherland, R. Lallo, G. L. Kay et al., Forensic Analysis Reveals Acute Decompensation of Chronic Heart Failure in a 3500-Year-Old Egyptian Dignitary, J Forensic Sci. sept, vol.61, issue.5, pp.1378-81, 2016.

A. Gabet, A. Lamarche-vadel, F. Chin, Y. De-peretti, C. Olié et al., Mortalité due à l'insuffisance cardiaque en France, Bull Epidémiol Hebd. 8 juill, pp.386-94, 2000.

. Authors/task-force-members, J. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur Heart J. 2 juill, vol.33, issue.14, pp.1787-847, 2012.

, L'insuffisance cardiaque / Maladies cardio-neuro-vasculaires / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil

. Disponible,

J. Trochu, Insuffisance cardiaque de l'adulte, Rev Prat. 15 janv, issue.1, pp.99-112, 2002.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al., 6-2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J. 14 juill, vol.37, issue.27, pp.2129-200, 2016.

M. Komajda, Management of heart failure: a challenge for healthcare systems

, Bull Acad Natl Med. juin, vol.196, issue.6, pp.1165-1167, 2012.

. Cohen, L'insuffisance cardiaque diastolique, Rev Prat. 20 sept, issue.7, pp.933-937, 2010.

. Disponible,

, Les cardiopathies ischémiques

, Cardiopathies valvulaires et congénitales graves chez l'adulte

J. Trochu, Insuffisance cardiaque de l'adulte, Rev Prat. 17 déc, vol.62, issue.10, pp.1433-1475, 2012.

C. Raphael, C. Briscoe, J. Davies, I. Whinnett, Z. Manisty et al., Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure, Heart. 1 avr, vol.93, issue.4, pp.476-82, 2007.

D. Lacroix, Collège national des enseignants de cardiologie (France), 2010.

J. T. Thibodeau, A. T. Turer, S. K. Gualano, C. R. Ayers, M. Velez-martinez et al., Characterization of a novel symptom of advanced heart failure: bendopnea, JACC Heart Fail. févr, vol.2, issue.1, pp.24-31, 2014.

A. Cohen and J. Wolf, Société française de cardiologie. Les fondamentaux de la pathologie cardiovasculaire: enseignement intégré, système cardiovasculaire, 2014.

R. Isnard, Physiopathologie de l'insuffisance cardiaque à l'usage du clinicien, Rev Prat. 20 sept, vol.60, pp.916-936, 2010.

. Société-française-de-pharmacologie-clinique, . De-thérapeutique, J. Bellien, and J. Cracowski, Collège national de pharmacologie médicale (France). Pharmacologie cardiovasculaire et respiratoire, 2016.

J. L. Cavalcante, S. Khan, and M. Gheorghiade, EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan. Expert Rev Cardiovasc Ther, vol.6, pp.1331-1339, 2008.

, Endothélines et antagonistes-Pharmacorama

. Disponible,

P. R. Kalra, J. Moon, and A. Coats, Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for nonselective endothelin antagonism in heart failure?, Int J Cardiol, vol.85, issue.2-3, pp.195-202, 2002.

C. Oddoze, Insuffisance cardiaque et peptides natriurétiques, SPECTRA Biol, issue.148, pp.41-47

S. A. Hubers and N. J. Brown, 3-Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition, Circulation. 15 mars, vol.133, issue.11, pp.1115-1139, 2016.

M. Kuhn, Molecular Physiology of Membrane Guanylyl Cyclase Receptors, Physiol Rev. avr, vol.96, issue.2, pp.751-804, 2016.

. Cohen, Etude ASCEND | Société Française de Cardiologie

D. G. Gardner, S. Chen, D. J. Glenn, and C. L. Grigsby, Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertens Dallas Tex 1979, mars, vol.49, issue.3, pp.419-445, 2007.

Y. Michiels, Insuffisance cardiaque, rôle du pharmacien, Actual Pharm, vol.55, issue.559, pp.44-51, 2016.

R. Isnard, N. Hammoudi, L. Legrand, and F. Pousset, Que retenir des dernières recommandations européennes sur l'insuffisance cardiaque chronique et aiguë ? Presse Médicale

. Disponible,

M. Komajda, Dossier: Traitement de l'insuffisance cardiaque, Rev Prat. mai, issue.5, pp.497-516, 2017.

H. Autorité-de-santé, Evaluation des défibrillateurs cardiaques automatiques implantables avec sonde(s) endocavitaire(s), 2015.

J. Aupetit, La resynchronisation dans l'insuffisance cardiaque chronique : à qui la proposer et comment en assurer le suivi ? Arch Mal Coeur Vaiss-Prat, p.7, 2009.

R. Dorent, C. Cantrelle, C. Jasseron, and C. Legeai, La greffe cardiaque en France : bilan actuel, Presse Médicale. 1 juill, vol.43, issue.7, pp.813-835, 2014.

T. Jy, La réadaptation dans l'insuffisance cardiaque-Quels bénéfices ? Pour quels patients ? | Cardiologie Pratique

F. Harcaute-e,-picard, F. Bauer, P. Assyag, Y. Bourgueil, and J. Thebaut, Dossier : insuffisance cardiaque, Concours Méd. 22 mars, issue.6, pp.231-240, 2010.

M. Van-craenenbroeck and E. , Exercise training as therapy for chronic heart failure

, Cardiology-Practice/Volume-14/Exercise-training-as-therapy-for-chronic-heart-failure

. , 879 du 21 juillet 2009 portant réforme de l'hôpital et relative aux patients, à la santé et aux territoires-Article, vol.84, 2009.

P. Jourdain, Y. Juillière, S. Hany, N. Hrynchyshyn, and M. Desnos, Éducation thérapeutique des patients atteints d'insuffisance cardiaque, Médecine Mal Métaboliques. 1 déc, vol.8, issue.6, pp.581-587, 2014.

Y. Juillière, P. Jourdain, C. Suty-selton, T. Béard, V. Berder et al., Therapeutic patient education and all-cause mortality in patients with chronic heart failure: A propensity analysis, Int J Cardiol. sept, vol.168, issue.1, pp.388-95, 2013.

B. Bozkurt and D. L. Mann, The Treatment of Heart Failure in the 21st Century: Is the Glass Half Empty or Half Full?, Methodist DeBakey Cardiovasc J, vol.9, issue.1, pp.3-5, 2013.

E. H. Howell and S. J. Cameron, Neprilysin inhibition: a brief review of past pharmacological strategies for heart failure treatment and future directions, Cardiol J. 26 sept, 2016.

P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. Cleland et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J. 14 juill, vol.37, issue.27, pp.2129-200, 2016.

A. Bachelot, N. Chabbert-buffet, S. Salenave, V. Kerlan, and M. Galand-portier, Les traitements anti-androgènes, Ann Endocrinol. févr, vol.71, issue.1, pp.20-26, 2010.

P. De-groote, Traiter l'insuffisance cardiaque systolique, Rev Prat Médecine Générale. mai, vol.26, issue.882, pp.419-443, 2012.

C. Caulin, I. Roguet, and S. A. Vidal, Vidal Recos: recommandations en pratique 2016 : 185 stratégies thérapeutiques, 2015.

K. F. Adams, J. K. Ghali, H. Patterson, J. Stough, W. G. Butler et al., A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile: Re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure, Eur J Heart Fail. mai, vol.16, issue.5, pp.483-93, 2014.

E. Uijl, L. Roksnoer, E. J. Hoorn, and A. Danser, 19-From ARB to ARNI in Cardiovascular Control, Curr Hypertens Rep. déc, vol.18, issue.12, p.86, 2016.

A. J. Kenny, A. Bourne, and J. Ingram, 22-Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24, vol.11

, Biochem J. 1 avr, vol.291, pp.83-91, 1993.

A. Bayes-genis and J. Lupón, 23-Neprilysin: Indications, Expectations, and Challenges, Rev Espanola Cardiol Engl Ed. juill, vol.69, issue.7, pp.647-656, 2016.

L. Papadimitriou, C. E. Hamo, and J. Butler, 24-Heart failure guidelines: What's new?, Trends Cardiovasc Med. juill, vol.27, issue.5, pp.316-339, 2017.

E. Kaplinsky, 20-Sacubitril/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis, vol.7, pp.278-90, 2016.

J. Minguet, G. Sutton, C. Ferrero, T. Gomez, and P. Bramlage, 1-LCZ696 : a new paradigm for the treatment of heart failure?, Expert Opin Pharmacother. févr, vol.16, issue.3, pp.435-481, 2015.

J. Singh and C. C. Lang, 2-Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. Vasc Health Risk Manag, vol.11, pp.283-95, 2015.

J. B?lohlávek,

, Cas Lek Cesk, vol.154, issue.6, pp.269-71, 2015.

, Novartis Pharmaceuticals Corp. 8-ENTRESTO-Prescribing informations, 2015.

, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization | Novartis, Novartis Pharmaceuticals Corp. 9-Novartis' new heart failure medicine LCZ696, now called Entresto(TM)

D. J. Cada, D. E. Baker, and J. Leonard, 5-Sacubitril/Valsartan. Hosp Pharm, vol.50, pp.1025-1061, 2015.

M. P. Lefkowitz, 11-LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure, BMC Pharmacol Toxicol [Internet]. déc, 2015.

, Vidal 2017: le dictionnaire, 2017.

J. Gu, A. Noe, P. Chandra, S. Al-fayoumi, M. Ligueros-saylan et al., 13Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi), J Clin Pharmacol. avr, vol.50, issue.4, pp.401-415, 2010.

L. Gan, T. Langenickel, J. Petruck, K. Kode, I. Rajman et al., 16-Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor: The Journal of Clinical Pharmacology, J Clin Pharmacol. janv, vol.56, issue.1, pp.78-86, 2016.

L. Fala, 17-Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure, Am Health Drug Benefits. sept, vol.8, issue.6, pp.330-334, 2015.

, Application number 207620Orig1s000. 25Medical review(s): LCZ696 (Entresto)

, European Medicines Agency. 29-Assessment report ENTRESTO, 2015.

H. A. Schoenfeld, T. West, P. B. Verghese, M. Holubasch, N. Shenoy et al., 30-The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-? concentrations and clearance in the cynomolgus monkey, Toxicol Appl Pharmacol. 15 mai, vol.323, pp.53-65, 2017.

A. M. Feldman, J. A. Haller, and S. T. Dekosky, 31-Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations, JAMA. 5 janv, vol.315, issue.1, pp.25-31, 2016.

Y. Hua, I. Wang, B. Liu, D. J. Kelly, C. Reid et al., 28-Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development, Future Cardiol. mars, vol.13, issue.2, pp.103-118, 2017.

M. B. Andersen, U. Simonsen, M. Wehland, J. Pietsch, and D. Grimm, 32-LCZ696 (Valsartan/Sacubitril)-A Possible New Treatment for Hypertension and Heart Failure, Basic Clin Pharmacol Toxicol. janv, vol.118, issue.1, pp.14-22, 2016.

S. Ayalasomayajula, T. Langenickel, P. Pal, S. Boggarapu, and G. Sunkara, Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin ReceptorNeprilysin Inhibitor, Clin Pharmacokinet, vol.17, issue.2017

. Disponible,

M. Senni, J. Mcmurray, R. Wachter, H. F. Mcintyre, A. Reyes et al., 33Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a doubleblind, randomized comparison of two uptitration regimens, Eur J Heart Fail. sept, vol.18, issue.9, pp.1193-202, 2016.

J. Mcmurray, M. Packer, A. S. Desai, J. Gong, M. P. Lefkowitz et al., 34Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med. 11 sept, vol.371, issue.11, pp.993-1004, 2014.

J. Mcmurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Böhm et al., 35ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC, Eur J Heart Fail. août, vol.14, issue.8, pp.803-69, 2012.

J. Bédard, V. Couillard-montminy, and S. Lefebvre, Comparaison entre l'énalapril et un inhibiteur du récepteur de l'angiotensine et de la néprilysine pour le traitement de l'insuffisance cardiaque, Pharmactuel, vol.49, issue.1, pp.33-40, 2016.

S. Yandrapalli, W. S. Aronow, P. Mondal, and D. R. Chabbott, Limitations of Sacubitril/Valsartan in the Management of Heart Failure, Am J Ther. avr, vol.24, issue.2, pp.234-243, 2017.

L. Correia and A. Rassi, Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?, Arq Bras Cardiol. janv, vol.106, issue.1, pp.77-86, 2016.

, European Medicines Agency. Summary of the risk management plan (RMP) for

. Entresto, , 2015.

, Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure, European Medicines Agency. Questions and answers on the risk management plan summary, p.12, 2016.

. Haute-autorité-de-santé and . Commission, Saint-Denis La Plaine : HAS; 2017 janv, 2017.

E. M. Screever, W. C. Meijers, D. J. Van-veldhuisen, and R. A. De-boer, New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations, Expert Opin Pharmacother. mai, vol.18, issue.7, pp.645-55, 2017.

L. C. Liu, B. Dorhout, P. Van-der-meer, J. R. Teerlink, and A. A. Voors, Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure, Expert Opin Investig Drugs. 2 janv, vol.25, issue.1, pp.117-144, 2016.

V. J. Planelles-herrero, J. J. Hartman, J. Robert-paganin, F. I. Malik, and A. Houdusse, Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil, Nat Commun, vol.8, issue.1, p.13, 2017.

M. Metra and J. R. Teerlink, Heart failure. The Lancet, p.13, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01742064

. Disponible,

, Bargoin vincent. L'antidiabétique empagliflozine bientôt évaluée dans l'insuffisance cardiaque

. Medscape, , p.13, 2016.

L. Rédaction, Le bilan dramatique du traitement de l'insuffisance cardiaque en France

. Docbuzz, , 2012.